UNSPSC 51162617: Cloperastine

This classification denotes an antitussive agent with the molecular formula C20H24ClNO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 69M5L7BXEK, chemically known as piperidine, 1-(2-((p-chloro-alpha-phenylbenzyl)oxy)ethyl)- but more generally known as cloperastine, which bears US NIH Compound Identifier 2805. European Medicines Agency schedules Cloperastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06737MIG.

UNSPSC 51162617 Cloperastine is a Commodity code that encompasses pharmaceutical products, though state and local solicitations under this code tag a broader range of pharmaceutical procurement including naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesaler channels. State and local governments buy these items to support community health initiatives, emergency response programs, and ongoing healthcare operations across county health departments, state pharmaceutical distribution networks, and multi-state cooperative purchasing alliances. The issuing bodies include county health agencies, state departments of administration managing cooperative purchasing, and multi-state consortia such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which serves participating state and local government facilities across multiple jurisdictions.

Recent activity shows procurement concentrated in Florida and the upper Midwest, with MMCAP coordinating multi-state procurement for Minnesota, Oregon, and participating members. Seminole County, Florida issued an IFB (Solicitation Number IFB60459723LAS, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford. MMCAP issued an RFP (Solicitation Number S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with awarded vendors effective July 1, 2026. Both procurements require vendors to meet cGMP certification, comply with FDA requirements and the Drug Supply Chain Security Act (DSCSA), and maintain substantial insurance coverage including commercial general liability of $2,000,000 to $5,000,000 per occurrence.